REFERENCE FILE
Liraglutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- The label warns about severe gastrointestinal reactions.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Saxenda: weight management for eligible patients.
A SECOND LOOK
A question to carry into the reading
Approach the liraglutide references by drawing a boundary around the people a statement describes. If a source reports results from a defined group, identify the conditions for entering that group and any exclusions relevant to your question. Keep those conditions attached when you summarize the result. Ask what would need to be established before extending the statement to someone outside that boundary. You do not have to decide whether the extension is justified on your own. A useful reading note can simply identify the proposed extension, the information it requires, and where the citation stops answering your question.
Questions to keep beside the page
- Who is included in the group described by this particular source?
- Which eligibility condition could limit the question I am trying to answer?
- What additional support would be needed to extend the statement beyond that group?
Sources for this file
- SAXENDANLM · Checked
FROM THE REFERENCE DESK